Exenatide

Jun 13, 2020

Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

Apr 04, 2019

Oramed Patent Allowed in the U.S. for Oral Exenatide

Mar 21, 2019

North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

Jul 16, 2018

Peptron Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model

Jun 24, 2018

Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW

Apr 23, 2018

Peptron Expands Exclusive License with NIH to Support Developing SR-exenatide to Treat Neurodegenerative Diseases

Jan 10, 2018

BYDUREON® BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes

Dec 05, 2017

Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

Nov 17, 2017

Indian Peptides Market - Expected to Reach USD 883.0 Million in 2022

Sep 15, 2017

New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes

May 31, 2017

Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist